FY2028 Earnings Estimate for DNLI Issued By Leerink Partnrs

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Leerink Partnrs dropped their FY2028 EPS estimates for shares of Denali Therapeutics in a note issued to investors on Sunday, November 9th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $0.50 for the year, down from their prior estimate of $0.55. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Denali Therapeutics’ FY2029 earnings at $0.80 EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. Denali Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.63) earnings per share.

DNLI has been the topic of a number of other reports. JPMorgan Chase & Co. raised their price objective on Denali Therapeutics from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley decreased their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Denali Therapeutics in a report on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $32.64.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $17.52 on Tuesday. The stock has a market capitalization of $2.57 billion, a P/E ratio of -6.02 and a beta of 1.39. The business has a 50-day moving average of $15.17 and a two-hundred day moving average of $14.72. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $30.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79.

Institutional Trading of Denali Therapeutics

Several institutional investors have recently made changes to their positions in the business. Barclays PLC raised its position in Denali Therapeutics by 2.6% in the third quarter. Barclays PLC now owns 437,001 shares of the company’s stock worth $6,345,000 after purchasing an additional 11,020 shares in the last quarter. Segall Bryant & Hamill LLC grew its stake in shares of Denali Therapeutics by 2.5% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 512,958 shares of the company’s stock valued at $7,448,000 after purchasing an additional 12,399 shares during the period. Fisher Asset Management LLC grew its stake in shares of Denali Therapeutics by 7.6% in the 3rd quarter. Fisher Asset Management LLC now owns 1,631,496 shares of the company’s stock valued at $23,689,000 after purchasing an additional 115,505 shares during the period. Rafferty Asset Management LLC raised its holdings in shares of Denali Therapeutics by 49.6% in the 3rd quarter. Rafferty Asset Management LLC now owns 182,886 shares of the company’s stock worth $2,656,000 after buying an additional 60,624 shares in the last quarter. Finally, Dana Investment Advisors Inc. lifted its position in shares of Denali Therapeutics by 42.6% during the 3rd quarter. Dana Investment Advisors Inc. now owns 50,716 shares of the company’s stock worth $736,000 after buying an additional 15,155 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.